PRAX Seeks Faster Development
Praxis Precision Medicines' seizure drug elsunersen receives Breakthrough Therapy Designation from the FDA after positive trial results
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
3 results loaded, newest first. End of these results.
PRAX: FDA Grants Breakthrough Therapy
Praxis Precision Medicines receives Breakthrough Therapy designation from FDA for Elsunersen to treat seizures associated with SCN2A development and epileptic encephalopathy
PRAX Receives FDA Breakthrough
Praxis Precision Medicines receives FDA Breakthrough Therapy Designation for Elsunersen to treat seizures associated with SCN2A developmental and epileptic encephalopathy